Infections in children with down syndrome and acute myeloid leukemia: a report from the Canadian infections in AML research group

Table 3 Factors associated with infection outcomes per course of chemotherapy (N = 157)

	Microbiologically documented sterile site infection		Bacteremia		Clinically documented infection
	Odds ratio (CI)	P value	Odds ratio (CI)	P value	Odds ratio (CI)	P value
Down syndrome-specific treatment protocol	0.42 (0.28, 0.64)	<0.0001	0.48 (0.29, 0.78)	0.003	0.25 (0.10, 0.60)	0.002
Age in years	1.01 (0.99, 1.03)	0.349	1.01 (0.98, 1.03)	0.577	1.01 (0.99, 1.03)	0.261
Diagnosed prior to January 1, 2000	0.79 (0.60, 1.03)	0.080	0.75 (0.56, 1.00)	0.052	0.95 (0.75, 1.22)	0.703
Cumulative dose of cytarabine (g/m²)	1.03 (1.02, 1.05)	0.0001	1.03 (1.01, 1.05)	0.001	0.99 (0.97, 1.01)	0.184
Neutropenia (ANC <0.5 ×10⁹) at start of course	1.01 (0.72, 1.43)	0.936	0.82 (0.56, 1.22)	0.336	1.88 (1.38, 2.56)	<0.0001
Greater than 15 days with neutropenia	2.50 (1.89, 3.32)	<0.0001	2.45 (1.83, 3.36)	<0.0001	2.81 (2.16, 3.66)	<0.0001
Days receiving steroids	1.08 (1.06, 1.11)	<0.0001	1.07 (1.05, 1.10)	<0.0001	1.07 (1.05, 1.09)	<0.0001

ISSN: 1750-9378